Insider

Johnson & Johnson reports new ERLEADA data before and after surgery

Johnson & Johnson said ERLEADA given before and after surgery reduced the risk of recurrence or death by 62% compared with surgery alone in patients with high-risk prostate cancer. For shareholders, this is an update on clinical data, but the source does not report a financial impact.

Verified against 2 archived primary sources · SHA-256 recorded Inspect sources & citations ↓
white wooden desk on hallway inside building
Photo by Brandon Holmes on Unsplash
62%
Lower recurrence risk
51%
Lower metastasis risk
77%
Overall response rate

Key points

  • In its headline, Johnson & Johnson said apalutamide before and after surgery was associated with a 62% lower risk of recurrence or death than surgery alone.
  • According to the company summary, twice as many patients in the group receiving apalutamide with androgen deprivation therapy before and after surgery remained free from further treatment at three years as in the surgery-alone group.
  • These are Johnson & Johnson headlines and short summaries, not full study results.

What the company reported

In its headline, Johnson & Johnson said apalutamide before and after surgery was associated with a 62% lower risk of recurrence or death than surgery alone. Separately, the summary reported a 51% lower estimated risk of metastasis or death with apalutamide and androgen deprivation therapy compared with immediate surgery. These are separate reported outcomes, not one figure.

What the summaries also say

According to the company summary, twice as many patients in the group receiving apalutamide with androgen deprivation therapy before and after surgery remained free from further treatment at three years as in the surgery-alone group. In another announcement, Johnson & Johnson reported an overall response rate of 77% for first-line RYBREVANT FASPRO in advanced head and neck cancer; 65% of responses were ongoing at the clinical cutoff, and the regimen is being studied in an ongoing Phase 3 trial.

What these data do not show

These are Johnson & Johnson headlines and short summaries, not full study results. They do not include participant numbers, absolute recurrence or metastasis rates, or detailed safety data, so the clinical scale of the reported differences cannot be assessed.

What to check next

The next step is to check the full presentations or publications for participant numbers, absolute results, follow-up duration and adverse events. For RYBREVANT FASPRO, readers should also watch for results from the ongoing Phase 3 trial; the summary does not say that it has been completed.

Original sources

  1. Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancerOctober 24, 2026SHA-256 of our archived copy ca88ac7b866a…
  2. RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancerOctober 25, 2026SHA-256 of our archived copy 385003f9ee85…
Cite this article

The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.

Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards